Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation

Vincenzo Mazzaferro, Riccardo Lencioni, Pietro Majno

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

In the treatment of early hepatocellular carcinoma (HCC), resection ablation and transplantation have had excellent initial success. Choices have to be based on a broad and long-term vision integrating-besides patients' interests-the community's needs and resources. In this scenario, guidelines such as the Barcelona Clinic Liver Cancer (BCLC) staging system can be viewed as a hideous frame (symbolized by the myth of Procrustes, Poseidon's son who stretched or maimed travelers to fit into his bed), or as a useful structure against which personalized or innovative treatments must be reality checked. In this article, the latter view is taken: For resection, portal hypertension must still represent a powerful caveat, particularly because of poor long-term results. Expansion of the criteria may instead be explored for multiple tumors and vascular invasion, where good indications can consistently be selected in expert surgical centers. For ablation, competitive results can be obtained although a small, but appreciable proportion of patients with early vascular invasion (∼ 10%), as they could probably benefit from anatomical resections. Conversely, ablative techniques overcoming the location and size limitations are developing and may prove competitive. For transplantation, several equivalent careful expansions of Milan's Criteria can be accepted, but as more patients have access to the waiting list-often prioritized on non-HCC indications-current allocation models prove to be insufficient, if not plainly inequitable, and should be revised.

Original languageEnglish (US)
Pages (from-to)415-426
Number of pages12
JournalSeminars in Liver Disease
Volume34
Issue number4
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Fingerprint

Hepatocellular Carcinoma
Transplantation
Blood Vessels
Waiting Lists
Neoplasm Staging
Portal Hypertension
Liver Neoplasms
Nuclear Family
Guidelines
Carcinoma
Therapeutics
Neoplasms

Keywords

  • hepatocellular carcinoma
  • liver resection
  • liver transplantation
  • radiofrequency ablation

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. / Mazzaferro, Vincenzo; Lencioni, Riccardo; Majno, Pietro.

In: Seminars in Liver Disease, Vol. 34, No. 4, 01.11.2014, p. 415-426.

Research output: Contribution to journalArticle

Mazzaferro, Vincenzo ; Lencioni, Riccardo ; Majno, Pietro. / Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation. In: Seminars in Liver Disease. 2014 ; Vol. 34, No. 4. pp. 415-426.
@article{529f19e57f1a4b1191d315110e4874a5,
title = "Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation",
abstract = "In the treatment of early hepatocellular carcinoma (HCC), resection ablation and transplantation have had excellent initial success. Choices have to be based on a broad and long-term vision integrating-besides patients' interests-the community's needs and resources. In this scenario, guidelines such as the Barcelona Clinic Liver Cancer (BCLC) staging system can be viewed as a hideous frame (symbolized by the myth of Procrustes, Poseidon's son who stretched or maimed travelers to fit into his bed), or as a useful structure against which personalized or innovative treatments must be reality checked. In this article, the latter view is taken: For resection, portal hypertension must still represent a powerful caveat, particularly because of poor long-term results. Expansion of the criteria may instead be explored for multiple tumors and vascular invasion, where good indications can consistently be selected in expert surgical centers. For ablation, competitive results can be obtained although a small, but appreciable proportion of patients with early vascular invasion (∼ 10{\%}), as they could probably benefit from anatomical resections. Conversely, ablative techniques overcoming the location and size limitations are developing and may prove competitive. For transplantation, several equivalent careful expansions of Milan's Criteria can be accepted, but as more patients have access to the waiting list-often prioritized on non-HCC indications-current allocation models prove to be insufficient, if not plainly inequitable, and should be revised.",
keywords = "hepatocellular carcinoma, liver resection, liver transplantation, radiofrequency ablation",
author = "Vincenzo Mazzaferro and Riccardo Lencioni and Pietro Majno",
year = "2014",
month = "11",
day = "1",
doi = "10.1055/s-0034-1394365",
language = "English (US)",
volume = "34",
pages = "415--426",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "4",

}

TY - JOUR

T1 - Early hepatocellular carcinoma on the procrustean bed of ablation, resection, and transplantation

AU - Mazzaferro, Vincenzo

AU - Lencioni, Riccardo

AU - Majno, Pietro

PY - 2014/11/1

Y1 - 2014/11/1

N2 - In the treatment of early hepatocellular carcinoma (HCC), resection ablation and transplantation have had excellent initial success. Choices have to be based on a broad and long-term vision integrating-besides patients' interests-the community's needs and resources. In this scenario, guidelines such as the Barcelona Clinic Liver Cancer (BCLC) staging system can be viewed as a hideous frame (symbolized by the myth of Procrustes, Poseidon's son who stretched or maimed travelers to fit into his bed), or as a useful structure against which personalized or innovative treatments must be reality checked. In this article, the latter view is taken: For resection, portal hypertension must still represent a powerful caveat, particularly because of poor long-term results. Expansion of the criteria may instead be explored for multiple tumors and vascular invasion, where good indications can consistently be selected in expert surgical centers. For ablation, competitive results can be obtained although a small, but appreciable proportion of patients with early vascular invasion (∼ 10%), as they could probably benefit from anatomical resections. Conversely, ablative techniques overcoming the location and size limitations are developing and may prove competitive. For transplantation, several equivalent careful expansions of Milan's Criteria can be accepted, but as more patients have access to the waiting list-often prioritized on non-HCC indications-current allocation models prove to be insufficient, if not plainly inequitable, and should be revised.

AB - In the treatment of early hepatocellular carcinoma (HCC), resection ablation and transplantation have had excellent initial success. Choices have to be based on a broad and long-term vision integrating-besides patients' interests-the community's needs and resources. In this scenario, guidelines such as the Barcelona Clinic Liver Cancer (BCLC) staging system can be viewed as a hideous frame (symbolized by the myth of Procrustes, Poseidon's son who stretched or maimed travelers to fit into his bed), or as a useful structure against which personalized or innovative treatments must be reality checked. In this article, the latter view is taken: For resection, portal hypertension must still represent a powerful caveat, particularly because of poor long-term results. Expansion of the criteria may instead be explored for multiple tumors and vascular invasion, where good indications can consistently be selected in expert surgical centers. For ablation, competitive results can be obtained although a small, but appreciable proportion of patients with early vascular invasion (∼ 10%), as they could probably benefit from anatomical resections. Conversely, ablative techniques overcoming the location and size limitations are developing and may prove competitive. For transplantation, several equivalent careful expansions of Milan's Criteria can be accepted, but as more patients have access to the waiting list-often prioritized on non-HCC indications-current allocation models prove to be insufficient, if not plainly inequitable, and should be revised.

KW - hepatocellular carcinoma

KW - liver resection

KW - liver transplantation

KW - radiofrequency ablation

UR - http://www.scopus.com/inward/record.url?scp=84928552893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928552893&partnerID=8YFLogxK

U2 - 10.1055/s-0034-1394365

DO - 10.1055/s-0034-1394365

M3 - Article

VL - 34

SP - 415

EP - 426

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 4

ER -